RxDoctor Payments Data

Rishi Vora, DO

Interventional Pain Medicine · Eugene, ORNPI 1730575119

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (53.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 22.4%. Reporting peaked in 2023 at $4,893 and has fallen 65.7% since, to $1,679 in 2025.

$16,070in general payments, 2019–2025

Across 358 payments — averaging $44.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$3K
  • Abbott$2K
  • Saluda Medical Americas, Inc.$2K
  • Painteq LLC$1K
  • Relievant Medsystems, Inc.$1K
  • plus $3K from 24 others

What the payments were for

  • Consulting fees$400%
  • Travel & lodging$6,77542%
  • Food & beverage$8,63554%
  • Education$6204%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,070 in reported general payments places this provider in the 85th percentile of 22 interventional pain medicine providers in Oregon.

See all interventional pain medicine providers in Oregon

Medicare billing

Part B allowed, 2024
$247,537
Medicare patients
357
Services billed
6,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine Hcl84$3,873
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen133$3,594
Buprenorphine13$3,484
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen69$2,138
Morphine Sulfate ErMorphine Sulfate61$1,596
Gabapentin85$1,591
Oxycodone Hcl123$1,565
Pregabalin54$1,122
Fentanyl13$1,045
Tizanidine Hcl70$882
Tramadol Hcl66$547
Cyclobenzaprine Hcl56$474
Methocarbamol50$401
Baclofen34$390
Meloxicam34$374

Paid to pharmacies, not to this prescriber.

Other interventional pain medicine in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →